0001819790-24-000046.txt : 20240319 0001819790-24-000046.hdr.sgml : 20240319 20240319190551 ACCESSION NUMBER: 0001819790-24-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wahl Bryan CENTRAL INDEX KEY: 0001841401 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 24765689 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wk-form4_1710889541.xml FORM 4 X0508 4 2024-03-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001841401 Wahl Bryan C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 0 1 0 0 General Counsel 0 Common Stock 2024-03-15 4 M 0 12038 A 45387 D Common Stock 2024-03-18 4 S 0 4436 30.60 D 40951 D Restricted Stock Units 2024-03-15 4 M 0 4790 0 D Common Stock 4790 9580 D Restricted Stock Units 2024-03-15 4 M 0 7248 0 D Common Stock 7248 21745 D The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Includes 1,383 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2023. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. /s/ Jeffrey Farrow, Attorney-in-Fact 2024-03-19